Researchers at WHV in collaboration with Waisman Biomanufacturing successfully completed manufacturing of DNA component of the PDPHV vaccine candidate.
PDPHV is WHV’s investigational vaccine, which is comprised of five DNA plasmids and four gp120 Env recombinant proteins and is being tested as a prime-boost regimen or co-administered in repeated doses, in healthy adult volunteers.
Previously, Waisman demonstrated that their proprietary plasmid manufacturing technology can be used to produce WHV’s DNA vaccine in higher yields and improved purity as compared to previous approaches. Over the past year, WHV worked with Waisman to produce all five plasmids, and now these plasmids were tested and mixed to generate the final product.
PDPHV is the first and only HIV vaccine candidate to use a multivalent approach with HIV Env proteins from the four major clades or strains of HIV. The PDPHV vaccine is currently being tested by the HIV Vaccine Trials Network (HVTN) in a Phase I clinical trial HVTN 124. The completion of DNA manufacturing is an important step on the path to the next stage of clinical testing of the vaccine candidate.
